You are here

In Utero Transplantation of Amniotic Fluid Stem Cells

The in-utero transplantation of hematopoietic stem cells for the prenatal treatment of congenital hematological diseases suffers from sub‐therapeutic levels of long‐term hematopoietic engraftment. However, a recent STEM CELLS study from the lab of Paolo De Coppi (UCL Great Ormond Street Institute of Child Health, London, UK) now suggests that amniotic fluid stem cells (AFSC) may represent a better stem cell choice in this case. Loukogeorgakis et al. that the in-utero transplantation of expanded autologous/congenic AFSCs results in a level of stable, multi‐lineage, long‐term hematopoietic engraftment significantly higher to that achieved with bone marrow‐derived cells. Therefore, the authors anticipate that this novel strategy may find use in a range of inherited disorders of hematopoiesis.